On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- Spinal Traction Market 2019 Growth Strategies, Size, Revenue Status, Demand, Business Opportunities, Segments and Forecast to 2023on September 6, 2019 at 5:05 am
The market has been segmented into herniated discs, sciatica, facet disease, slipped discs, bone spurs, foraminal stenosis, pinched nerves, and degenerative disc disease, based on applications. The ...
- Orthopedic Devices Market Growth, Analytical Overview, Growth Factors, Demand and Trends Forecast to 2025on September 6, 2019 at 12:31 am
These procedures are becoming more common and less costly with time and therefore despite of being among the oldest orthopedic therapeutic offering, their market is still growing at a steady ...
- Topographic modeling of early human osteoarthritis in sheepon September 4, 2019 at 11:41 am
induced meniscal injury in sheep and created detailed maps of disease progression. They found that cartilage and bone breakdown occurred first in the injured region before spreading throughout the ...
- SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuseon September 3, 2019 at 5:00 am
Sept. 03, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy ...
- New Academic Delphi Panel Formed to Define Best Practices for Using Bone Marrow Concentrateon September 3, 2019 at 4:08 am
such as degenerative disc disease. However, this will only occur with rigorous scientific studies, innovation and collaboration among leaders in the field. Patients are seeking these therapies from ...
- Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusionon September 2, 2019 at 10:00 pm
procedures in patients with degenerative disc disease, with autograft (patient’s own bone) as comparator. This IND application is considered the first ever approval by the FDA to evaluate a drug ...
- DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Diseaseon August 31, 2019 at 4:07 am
DDD is a painful, chronic and progressive disease that is ... bones together and/or replace bone or tissue altogether. However, back surgeries often have limited success and may result in subsequent ...
- Global Orthopedic Implants Market is Expected to Reach USD 8.97 Billion by 2025 : Fior Marketson August 29, 2019 at 2:29 am
There is an ongoing shift from conventional invasive procedures to minimally invasive surgeries for the treatment of orthopedic disabilities or diseases. The increasing prevalence of orthopedic ...
- The Bright Future of Stem Cell Therapy: Part Ion August 28, 2019 at 10:00 am
holds the most promise for healing degenerative joints in addition to many other tissues and organ systems, including cardiac, autoimmune and neurologic diseases. MSCs can be harvested from one’s own ...
via Bing News